1 – 50 of 111
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Non-Fungible Tokens as a Framework for Sustainable Innovation in Pharmaceutical R&D: A Smart Contract-Based Platform for Data Sharing and Rightsholder Protection
(
- Contribution to journal › Article
- 2023
-
Mark
Governing, Protecting, and Regulating the Future of Genome Editing : The Significance of ELSPI Perspectives
Slokenberga, Santa ; Minssen, Timo and Nordberg, Ana LU (2023)
- Book/Report › Anthology (editor)
-
Mark
Introduction : The significance of ELSPI perspectives in governing, protecting, and regulating the future of genome editing
2023) p.1-14(
- Chapter in Book/Report/Conference proceeding › Book chapter
- 2022
-
Mark
Governing, protecting, and regulating the future of genome editing : The significance of ELSI perspectives
(
- Contribution to journal › Article
-
Mark
Governing, Protecting, and Regulating the Future of Genome Editing : The Significance of ELSPI Perspectives
(
- Contribution to journal › Scientific review
-
Mark
Balancing innovation, ‘ordre public’ and morality in human germline editing : A call for more nuanced approaches in patent law
(
- Contribution to journal › Article
-
Mark
Ecosystem effectuation : creating new value through open innovation during a pandemic
(
- Contribution to journal › Article
- 2021
-
Mark
The Role of Patents and Licensing in the Governance of Human Genome Editing: A White Paper
2021)(
- Book/Report › Report
- 2020
-
Mark
Rules and Tools in the Battle against Superbugs - A call for integrated strategies and enhanced international collaboration to promote antimicrobial drug development
2020) p.111-136(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
SWEDEN’s Response to COVID-19: A tale of trust, recommendations, and odorous nudges: Available at: https://blog.petrieflom.law.harvard.edu/2020/05/12/sweden-global-responses-covid19/
2020)(
- Other contribution › Miscellaneous
-
Mark
AIRR Data Under the E.U. Trade Secrets Directive: Aligning Scientific Practices with Commercial Realities
2020) p.239-268(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
When does stand-alone software qualify as a medical device in the European Union?: The CJEU decision in SNITEM and what it implies for the next generation of medical devices
(
- Contribution to journal › Article
-
Mark
Ethical and Legal Challenges of Artificial Intelligence-Driven Health Care
2020) p.295-336(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Clinical trial data transparency and GDPR compliance: Implications for data sharing and open innovation
2020) In Science and Public Policy(
- Contribution to journal › Article
-
Mark
Germany’s digital health reforms in the COVID-19 era: lessons and opportunities for other countries
(
- Contribution to journal › Article
-
Mark
ELSI Implications of Prioritizing Biological Therapies in the Times of COVID-19
(
- Contribution to journal › Article
-
Mark
Book introduction: An Appraisal of the EU Directive on Trade Secrets
2020) p.1-7(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
The harmonization and protection of trade secrets in the EU: – An Appraisal of the EU Directive
2020)(
- Book/Report › Book
-
Mark
Denmark
2020) p.113-128(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Knowledge transfer for large scale vaccine manufacturing
(
- Contribution to journal › Article
-
Mark
The European Artificial Intelligence Strategy: Implications and Challenges for Digital Health
(
- Contribution to journal › Article
-
Mark
Lost on the High Seas without a Safe Harbor or a Shield? Navigating Cross-Border Data Transfers in the Pharmaceutical Sector After Schrems II Invalidation of the EU-US Privacy Shield
(
- Contribution to journal › Article
-
Mark
The EU-US Privacy Shield Regime for Cross-Border Transfers of Personal Data under the GDPR: What are the legal challenges and how might these affect cloud-based technologies, big data, and AI in the medical sector?
(
- Contribution to journal › Article
-
Mark
Regulatory responses to medical machine learning
(
- Contribution to journal › Article
-
Mark
One year after Vanda, are diagnostics patents transforming into methods of treatment to overcome Mayo-based rejections?
(
- Contribution to journal › Article
-
Mark
At the Epicentre of COVID-19 - the Tragic Failure of the Global Supply Chain for Medical Supplies
2020) In Frontiers in Public Health(
- Contribution to journal › Article
-
Mark
A qualitative study of biosimilar manufacturer and regulator perceptions on intellectual property and abbreviated approval pathways
(
- Contribution to journal › Article
-
Mark
Social, cultural and economic aspects of antimicrobial resistance
(
- Contribution to journal › Article
-
Mark
Preparing for antimicrobial resistance in the wake of the COVID-19 pandemic: The vision and “social science” mission of the INAMRSS network
2020)(
- Other contribution › Web publication
-
Mark
An EU Comparative Analysis of the Regulation of Clinical Trials Supervisory Bodies in the Aftermath of Regulation 536/2014
(
- Contribution to journal › Article
-
Mark
Establishing the First International Genetic Discrimination Observatory
(
- Contribution to journal › Article
- 2019
-
Mark
The Legal Dimensions of Big Data, Artificial Intelligence and Machine Learning in Pharmaceutical Innovation (original title in accepted version): Editorial to special issue of the European Pharmaceutical Law Review on "Big Data, AI & Machine Learning in Pharmaceutial Innovation"
(
- Contribution to journal › Article
-
Mark
The problem with antibiotics
(
- Contribution to journal › Article
-
Mark
What lurks in the shadows of the openness hyperbole for biopharmaceuticals?
2019) In Drug Development Research(
- Contribution to journal › Debate/Note/Editorial
-
Mark
An Update on Research- & Bolar exemptions in the U.S. and Europe: Unsolved questions and new developments in an increasingly important area of law
(
- Contribution to journal › Article
-
Mark
Is Data Sharing Caring Enough About Patient Privacy?: Part I: The Background
2019)(
- Other contribution › Miscellaneous
-
Mark
An "export-only" exception to pharmaceutical patents in Europe: Should the U.S. follow suit?
(
- Contribution to journal › Article
-
Mark
Nudges or Shoves in the Secondary Use of Health Data: What is the More Desirable Approach? (Part 2)
2019)(
- Other contribution › Miscellaneous
-
Mark
Nudges or Shoves in the Secondary Use of Health Data: What is the More Desirable Approach? (Part I)
2019)(
- Other contribution › Miscellaneous
-
Mark
Global Genes, Local Concerns: Legal, Ethical and Scientific Challenges in International Biobanking
2019)(
- Book/Report › Book
-
Mark
Much ado about something. Legal, ethical, and scientific challenges in international biobanking and translational exploitation
2019) 1.(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Mayo’s impact on patent applications related to biotechnology, diagnostics and personalized medicine
(
- Contribution to journal › Article
-
Mark
Shadow health records meet new data privacy laws
(
- Contribution to journal › Article
-
Mark
Homomorphic Encryption: The ‘Holy Grail’ for Big Data Analytics & Legal Compliance in the Pharmaceutical and Healthcare Sector?
(
- Contribution to journal › Article
-
Mark
Regulating Germline Editing in Assisted Reproductive Technology : An EU Cross-disciplinary Perspective
(
- Contribution to journal › Article
-
Mark
How does emerging patent case law in the US and Europe affect precision medicine?
(
- Contribution to journal › Article
-
Mark
AIPPI Report for Denmark on Plausibility in Patent Law: AIPPI 2019 - 2019 Study Questions - Plausibility
2019)(
- Book/Report › Book
- 2018
-
Mark
Big Data and intellectual property rights in the health and life sciences
2018) p.311-323(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
A Ray of Light in Muddy Waters? -The CJEU rules on combination SPCs in C-121/17 Teva v Gilead
(
- Contribution to journal › Article
-
Mark
How much is too much?- Defining the Metes and Bounds of Excessive Pricing in the Pharmaceutical Sector
(
- Contribution to journal › Article